

THE BREAKING NEWS

Paradigm Shift in Prostate Cancer Management



PRACTICE-CHANGING RESULTS FOR METASTATIC PROSTATE CANCER IN 2014

June 01, 2014

CHICAGO — For patients with metastatic hormone-sensitive prostate cancer, upfront chemotherapy with docetaxel, given at the same time as hormone therapy instead of later, prolongs survival. This finding, from the ECOG E3805 CHAARTED trial, is being described as "practice-changing" and "transformative".

"In prostate cancer, I am not aware of a historic study that ever offered up this magnitude of improvement in survival," said ASCO president Clifford Hudis, MD, during the press briefing. "Quite frankly," he said, "across all of solid tumors, this is an almost unprecedented improvement in median survival."

"I anticipate that it will change practice," said Andrew Armstrong, MD, associate professor of medicine and surgery at the Duke Cancer Institute in Durham, North Carolina.

Reference:

1. Practice-Changing Results for Metastatic Prostate Cancer, 2014. at <http://www.medscape.com/viewarticle/826018>. (Accessed 11-November, 2014)



PARADIGM SHIFT IN PROSTATE CANCER MANAGEMENT

Date:

16th December 2014 (Tuesday)

Time:

19:00-22:00

Location:

Salon I-III Hyatt Regency Hong Kong, Tsim Sha Tsui

LECTURE

Agenda:

19:00 – 19:15 Reception

19:15 – 20:00 Management of Castration Sensitive Metastatic Prostate Cancer

Speaker:

Dr. Christopher Sweeney, Associate Professor, Department of Medicine, Harvard Medical School

20:00 – 20:10 Local experience sharing on multi-modality approach in metastatic prostate cancer after CHAARTED study

Speaker:

Prof. Anthony CF Ng, Specialist in Urology, Department of Surgery, The Chinese University of Hong Kong

20:10 – 20:25 Discussion

20:25 – 22:00 Dinner

CME pending:

-Hong Kong College of Radiologists
-Hong Kong College of Physicians

-Hong Kong College of Surgeons

- MCHK programme

INVITATION

Enhancing existing therapies – Entering the era of breakthrough in metastatic prostate cancer

A major breakthrough has just taken place in the management of castration sensitive metastatic prostate cancer. For the first time, early intervention has had a major effect on both survival and time to disease progression. Impressively, these exciting outcomes were achieved by a new regimen rather than using a conventional approach.

We are pleased to invite you to a distinctive educational symposium about this early intervention. Our distinguished guest speakers are Dr. Christopher Sweeney – the lead investigator of the CHARTED study and also the Associate Professor at the Harvard medical school, he will share with us the latest clinical data and Prof. Anthony CF Ng, our local expert, will talk on his local experience.

We look forward to seeing you at the meeting and hope this will value add to your clinical practice.

INVITED BY

Dr. Leung Yiu Lam, Simon
Specialist in Urology

Dr. Leung Kwong Chuen, Angus
Specialist in Clinical Oncology

ORGANIZED BY



E	Postage Paid Hong Kong	Permit No. 2896
---	---------------------------	-----------------------

ECONOMY

CONFIRMATION OF PARTICIPATION

I shall be able to attend the following:

<input type="checkbox"/>	LECTURE ONLY	<input type="checkbox"/>	DINNER + LECTURE
--------------------------	--------------	--------------------------	------------------

Name:

Name of hospital/
Clinic:

Contact number/
Email:

Registration: R.S.V.P Ms. Portia Lee on or before 12th Dec, 2014
Phone: 2506 8426; Fax: 2506 2537

sanofi-aventis Hong Kong Limited
Units 706-710, Level 7, Core C, Cyberport 3,
100 Cyberport Road, Hong Kong.
Tel : (852) 2506-8333 Fax : (852) 2506-2537

SUPPORTED BY

SANOFI ONCOLOGY

